Introduction {#s1}
============

Since 2000, there has been substantial increase in international financing for global health from donor governments and innovative financing, in particular for infectious diseases.[@pone.0105722-Atun1]

While the Organization for Economic Cooperation and Development (OECD) tracks donor contributions to overseas development assistance for health, including for selected infectious diseases, there are no internationally adopted systems for tracking innovative financing^1^ or investments in infectious disease research for addressing global health burden, by countries, or by funding entities. To date, few studies have analysed research and development (R&D) investments.[@pone.0105722-Head1]--[@pone.0105722-Fisk1]

Annual global research and development (R&D) funding for neglected diseases,[@pone.0105722-Moran1] and funding by the National Institutes of Health (NIH) of the United States (US) Department of Health and Human Services have been estimated for selected years.[@pone.0105722-Gross1]--[@pone.0105722-Gillum1] A recent systematic analysis of infectious disease research investments in the United Kingdom (UK) from 1997 to 2010 and burden of disease in 2004 and 2008 revealed mismatches between the amounts of funds invested and the burden of disease caused by the conditions, raising concerns about the efficiency of allocation of the investments in infectious disease R&D.[@pone.0105722-Head1],[@pone.0105722-Kyratsis1]

The World Health Organization (WHO) Consultative Expert Working Group on Research and Development: Financing and Coordination is currently reviewing the feasibility of establishing a global observatory to monitor R&D investments.[@pone.0105722-WHO1]--[@pone.0105722-WHO2] The initiative was endorsed by member states at the sixty-sixth World Health Assembly this year.

We present the first systematic and comprehensive analysis of investments in infectious disease R&D over the 14-year period from 1997 to 2010. Specifically, the analysis focuses on investment patterns by global health institutions funding infectious disease research.

Methods {#s2}
=======

We obtained data from several sources for infectious disease research studies where funding was awarded between 1997 and 2010 (full list and further resources on methodology are openly available from <http://researchinvestments.org/data>). [Figure 1](#pone-0105722-g001){ref-type="fig"} shows the sources of data and the numbers of studies explored at each stage of screening to reach the final set of studies for detailed analysis. We identified 6165 relevant studies for analysis. We assigned each study to primary disease categories. We outline the methodology for the categorisation of disease areas and classification of the funding sources, elaborated in detail previously.[@pone.0105722-Head1]

![Sources and numbers of studies screened.\
BBSRC = Biotechnology and Biological Sciences Research Council. ESRC = Economic and Social Research Council. R&D = Research and Development. Total number of studies differs by n = 5 (0.08%) from previously published work following ongoing review of the data by the study team [@pone.0105722-Head1].](pone.0105722.g001){#pone-0105722-g001}

The overarching dataset was constructed by collating open-access data and directly contacting the major sources of public and philanthropic funding for infectious disease research studies, including the Wellcome Trust, Medical Research Council and other research councils, UK government departments, the European Commission, Bill and Melinda Gates Foundation, and other research charities. We also searched other databases, including Clinicaltrials.gov and the National Research Register. Within each category, we documented topic-specific subsections, including specific pathogen or disease. We allocated studies to one of four categories along the R&D continuum: pre-clinical; phases I, II or III; product development; and operational research (which includes epidemiological and implementation research). We developed nine major categories for funding organisations, based on total levels of research investment, and cross-referenced grants from funding organisation to disease categories and stage of R&D funding.

Global health studies include investments to UK institutions with a global partner organisation, or studies predominantly carried out or focused on a country other than the UK. Antimicrobial resistance includes antibacterial, antiviral, antifungal and antiparasitic studies. Reference to sexually transmitted infections excludes HIV/AIDS. Neglected tropical diseases (NTDs) were categorised based on the infections focused on by WHO (for the list of NTDs focused on by WHO see <http://www.who.int/neglected_diseases/diseases/en>). No private sector funding was included in this analysis as open-access data were limited.

Grants awarded in a currency other than pounds sterling were converted to UK pounds using the mean exchange rate in the year of the award (<http://www.oanda.com/currency/average>). All grant funding amounts were adjusted for inflation and reported in 2010 UK pounds.

We excluded studies not immediately relevant to infection, veterinary infectious disease research studies (unless there was a zoonotic component) those exploring the use of viral vectors to investigate non-communicable diseases, grants for symposia or meetings, or studies with UK contributions (e.g. as a collaborator), but the funding was awarded to a non-UK institution. Unfunded studies were excluded.

We used Microsoft Excel (versions 2000 and 2007) to categorize studies. Where needed, data were exported into Microsoft Access (versions 2000 and 2007) and specific keyword queries used to select precise sections of the data for analysis. We used Stata (version 11.0; StataCorp LP, Texas) for statistical analysis and to generate figures.

We then systematically analysed the investments by major funding organisations for research projects where a UK institution acted as a leading partner. For multi-centre collaborative studies, we included data where apportioned funding was indicated where UK institutions were the leading partner. For multi-centre collaborative studies where a UK institution was not a leading partner, we were unable to include the funding, which may represent an underestimate (particularly for studies led in the European Union or the United States). We used fold differences to measure the quantity of change in total investment, number of studies, mean grant, and median grant according to disease system, specific infection and funding organisation. We present median grants in the results section to minimize the effect of the skew from few, very large international project awards led by a UK institution.

We used nonparametric Mann-Whitney rank-sum test to assess the distribution of funding by funding source. Nonparametric K-sample test on equality of medians was applied to compare the median funding by funding source, and reported as a chi-squared statistic without Yates' correction for continuity. Nonparametric Wilcoxon signed-rank test was applied when comparing matched data, such as time trends by funding source. The significance for all tests was defined at the 5% level (two-sided *P* = 0.05).

Results {#s3}
=======

We identified 6165 funded studies in infectious disease research with total research investment of UK £2.6 billion. Of these, 2385 studies (38.7%) were investments by public research funding organisations totalling £1.4 billion (54%), 2874 studies (46.6%) by philanthropic funding organisations totalling £1.1 billion (42.4%).

Global health studies represented an investment of £928 million (35.7%). Overall, the mean amount of grant funding awarded was £421 733 (SD £1 315 935) and the median amount of grant funding awarded was £158 055 (IQR £49 490 -- £352 699).

[Figure 2](#pone-0105722-g002){ref-type="fig"} shows the overall ranking of funding organisations by total research investment. The Wellcome Trust was the leading investor in infectious disease research with £688 million (26.5%), closely followed by the UK Medical Research Council (MRC) with £673 million (25.9%). Major funding organisations included the European Commission with £255 million (9.8%), the Bill and Melinda Gates Foundation with £220 million (8.5%) and the Biotechnology and Biological Sciences Research Council (BBSRC) with £186 million (7.2%). Charities and smaller foundations collectively accounted for £193 million of investment (7.4%) across 851 studies (13.8%).

![Investment in immunology and vaccine research by funding organisation.\
BBSRC = Biotechnology and Biological Sciences Research Council. DH = Department of Health. MRC = Medical Research Council. Blue designates philanthropic funding organisations. Red designates public funding organisations. Yellow designates other funding organisations.](pone.0105722.g002){#pone-0105722-g002}

[Figure 3](#pone-0105722-g003){ref-type="fig"} shows the trends in research funding according to funding organisation over time. The Bill and Melinda Gates Foundation awarded the largest mean and median amount of grant funding at £5 664 699 (SD £8 966 093) and £1 488 432 (IQR £628 545 -- £5 576 863), respectively.

![Trends in investment over time: a) stratified by funding organisation, b) stratified by public versus philanthropic funder.\
BBSRC = Biotechnology and Biological Sciences Research Council. DH = Department of Health. MRC = Medical Research Council.](pone.0105722.g003){#pone-0105722-g003}

[Figure 4](#pone-0105722-g004){ref-type="fig"} compares the total investment and median amount of grant funding awarded by public and philanthropic investors. The public funding has been larger in 11 of the 14 years studied than philanthropic organisations, which accounts for a significant proportion of the funding ranging from 38% to 72% of total annual funding. Funding is volatile ranging, from ∼£40 million to ∼£160 million for the philanthropic organisations and ∼£30 million to ∼£230 million for the public funders. There is no obvious trend suggesting that the annual funding is increasing and has been fairly flat since 2005. The average median funding awarded by public organisations is larger at £255 992 (IQR £127 167 -- £529 610), compared with £146 060 (IQR £52 433 -- £286 518) for philanthropic organisation, almost two fold difference. [Figure 5](#pone-0105722-g005){ref-type="fig"} shows an overall increase in research funding, greatest for public funding organisations. However the levels of funding are volatile over time, and the linear regression best-fit line should be interpreted with caution.

![Trends in investment by public versus philanthropic funder over time: a) total research investment, b) median research investment.](pone.0105722.g004){#pone-0105722-g004}

![Fitted trend in investment by public versus philanthropic funder over time.\
Full line represents annual expenditure. Dotted line represents linear regression best-fit line over the 14-year study period.](pone.0105722.g005){#pone-0105722-g005}

 {#s4}

Funding along the research and development stages {#s4a}
-------------------------------------------------

[Table 1](#pone-0105722-t001){ref-type="table"} shows investment by funding source and research and development (R&D) stages. The funding for preclinical research accounted for the majority of investment with £1.6 billion (62.4%) with a median grant of £193 149 (IQR £74 157 -- £365 587). Public investors funded 57.5% of the research with philanthropic investors funding 40.5%.

10.1371/journal.pone.0105722.t001

###### Investment in immunology and vaccine research by funding source and research and development phase.

![](pone.0105722.t001){#pone-0105722-t001-1}

  Funder                                              Investment (total); £ (%)   Studies (total); n (%)   Mean grant (total); £ (SD)   Fold difference   Median grant (total); £ (IQR)   Fold difference   Pre-clinical investment; £ (%)   Pre-clinical median grant; £ (IQR)   Fold difference   Pre-clinical investment; n (%)   Phase 1--3 investment; £ (%)   Phase 1--3 median grant; £ (IQR)   Fold difference   Phase 1--3 investment; n (%)   Product development investment; £ (%)   Product development median grant; £ (IQR)   Fold difference   Product development investment; n (%)   Operational research investment; £ (%)   Operational research median grant; £ (IQR)   Fold difference   Operational research investment; n (%)
  -------------------------------------------------- --------------------------- ------------------------ ---------------------------- ----------------- ------------------------------- ----------------- -------------------------------- ------------------------------------ ----------------- -------------------------------- ------------------------------ ---------------------------------- ----------------- ------------------------------ --------------------------------------- ------------------------------------------- ----------------- --------------------------------------- ---------------------------------------- -------------------------------------------- ----------------- ----------------------------------------
  Public funding                                            1,403,579,619                 2,385                     588,503                  1.40                    255,992                   1.62                  932,404,084                          277,131                      1.43                     1,609                        109,137,486                        535,878                     2.51                      58                             69,119,547                                  236,824                         1.60                          131                                 292,918,502                                  177,645                          2.01                          587
                                                                54.0%                     38.7%                    1,447,668                                    127,167--529,610                                        66.4%                         156,125--543,951                                          67.5%                            7.8%                      130,994--1,413,252                                        2.4%                               4.9%                                 80,507--688,115                                                  5.5%                                    20.9%                                 51,765--417,210                                                   24.6%
  BBSRC                                                      186,268,429                   578                      322,264                  0.76                    253,398                   1.60                  186,243,256                          253,479                      1.31                      576                              0                                0                        0.00                      0                                   0                                         0                            0.00                           0                                     25,173                                     12,586                          0.14                           2
                                                                7.2%                       9.4%                     361,565                                     169,787--365,159                                        100.0%                        176,508--365,951                                          99.7%                            0.0%                                                                                0.0%                               0.0%                                                                                                  0.0%                                     0.0%                                   812--24,359                                                      0.3%
  DH                                                         134,961,745                   285                      473,550                  1.12                    203,544                   1.29                   14,317,188                          215,773                      1.12                       28                          6,840,563                         808,336                     3.79                      7                              20,373,031                                  291,554                         1.98                          40                                   93,430,963                                  175,134                          1.98                          210
                                                                5.2%                       4.6%                     846,024                                      72,628--514,066                                        10.6%                         57,538--556,546                                            9.8%                            5.1%                      140,714--1,712,753                                        2.5%                               15.1%                               101,275--707,126                                                  14.0%                                   69.2%                                 72,294--394,057                                                   73.7%
  European Commission                                        255,015,533                   219                     1,164,454                 2.76                    439,762                   2.78                  187,782,118                          195,999                      1.01                      164                              0                                0                        0.00                      0                              12,680,401                                  624,297                         4.23                          14                                   54,553,014                                  555,497                          6.30                           41
                                                                9.8%                       3.6%                    2,084,358                                   127,419--1,454,941              73.6%             119,659-- 1,449,573                                                   74.9%                     0.0%                                                                                       0.0%                     5.0%                         82298--1,504,880                                                               6.4%                         21.4%                             382,254--1,454,941                                                               18.7%       
  MRC                                                        672,895,698                   962                      699,476                  1.66                    366,479                   2.32                  527,370,055                          377,564                      1.95                      738                          42,323,395                        516,957                     2.42                      43                             27,578,378                                  403,037                         2.73                          35                                   75,623,870                                  272,221                          3.09                          146
                                                                25.9%                     15.6%                     993,012                                     199,287--713,178                                        78.4%                         210,390--713,178                                          76.7%                            6.3%                      126,839--1,073,076                                        4.5%                               4.1%                               100,528--1,072,094                                                 3.6%                                    11.2%                                 165719--562,944                                                   15.2%
  UK government, non-DH                                      154,438,214                   341                      452,898                  1.07                    110,178                   0.70                   16,691,467                          121,493                      0.63                      103                          59,973,528                       1,833,607                    8.59                      8                               8,487,737                                  127,733                         0.87                          42                                   69,285,483                                   81,566                          0.92                          188
                                                                5.9%                       5.5%                    2,811,384                                     19,073--206,784                                        10.8%                         19,851--206,784                                           30.2%                           38.8%                      84,889--3,059,723                                         2.3%                               5.5%                                 39,707--242,762                                                  12.3%                                   44.9%                                 15,547--194,524                                                   55.1%
  Philanthropic funding                                     1,102,469,932                 2,874                     383,601                  0.91                    146,060                   0.92                  656,630,852                          154,734                      0.80                     2,056                         27,387,963                        114,168                     0.53                      62                             50,456,146                                  168,035                         1.14                          109                                 367,994,932                                   80,028                          0.91                          647
                                                                42.4%                     46.6%                    1,377,079                                     52,433--286,518                                        59.6%                         67,894--283,391                                           71.5%                            2.5%                       22,900--355,370                                          2.2%                               4.6%                                 64,854--438,110                                                  3.8%                                    33.4%                                 18,846--253,342                                                   22.5%
  Bill & Melinda Gates Foundation                            220,923,242                    39                     5,664,699                 13.43                  1,488,432                  9.42                   40,318,109                         4,477,357                     23.18                      8                           4,747,473                         628,545                     2.94                      5                               5,407,891                                 1,262,055                        8.55                           4                                  170,449,769                                 1,569,951                         17.79                          22
                                                                8.5%                       0.6%                    8,966,093                                   628,545--5,576,863                                       18.2%                       1,053,145--6,794,265                                        20.5%                            2.1%                      355,370--1,226,250                                       12.8%                               2.4%                               927,326--1,776,619                                                 10.3%                                   77.2%                                                                                                   56.4%
  Charity                                                    193,459,157                   851                      227,332                  0.54                    87,318                    0.55                  130,381,297                          103,052                      0.53                      525                          4,993,262                          56,010                     0.26                      40                              3,620,490                                  65,676                          0.44                          35                                   54,464,109                                   51,531                          0.58                          251
                                                                7.4%                      13.8%                     730,057                                      27,616--167,829                                        67.4%                         48,134--190,307                                           61.7%                            2.6%                       14,252--131,102                                          4.7%                               1.9%                                 9,423--168,035                                                   4.1%                                    28.2%                                 11,000--116,503                                                   29.5%
  Wellcome Trust                                             688,087,494                  1,984                     346,818                  0.82                    168,434                   1.07                  485,931,447                          178,375                      0.92                     1,523                         17,647,229                        348,687                     1.63                      17                             41,427,765                                  289,781                         1.96                          70                                  143,081,054                                  107,626                          1.22                          374
                                                                26.5%                     32.2%                     646,625                                      66,419--335,557                                        70.6%                         81,881--315,033                                           76.8%                            2.6%                      116,470--1,660,204                                        0.9%                               6.0%                                 95,888--551,291                                                  3.5%                                    20.8%                                 28,364--340,503                                                   18.9%
  Other funding                                              93,936,339                    906                      103,683                  0.25                    28,626                    0.18                   33,510,841                           21,004                      0.11                      372                          10,301,944                        213,471                     1.00                      25                             13,303,136                                  38,625                          0.26                          95                                   36,820,418                                   30,531                          0.35                          414
                                                                3.6%                      14.7%                     273,102                                      6,282--105,082                                         35.7%                          5,917--81,491                                            41.1%                           11.0%                       23,805--305,339                                          2.8%                               14.2%                                10,000--1769,06                                                  10.5%                                   39.2%                                  6,280--95,139                                                    45.7%
  Overall                                                   2,599,985,851                 6,165                     421,733                                          158,055                                        1,622,545,777                         193,149                                               4,037                        146,827,393                        213,471                                              145                             132,878,829                                 147,621                                                       335                                 697,733,852                                   88,232                                                       1,648
                                                                                                                   1,315,935                                     49,490--352,699                                        62.4%                         74,157--365,587                                           65.5%                            5.6%                       53,116--839,713                                          2.4%                               5.1%                                 38,625--409,663                                                  5.4%                                    26.8%                                 18,513--250,423                                                   26.7%
  [Table 1](#pone-0105722-t001){ref-type="table"}.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

BBSRC = Biotechnology and Biological Sciences Research Council. DH = Department of Health. MRC = Medical Research Council.

Phase I, II, III clinical trials accounted for £147 million (5.6%) with the highest median grants at £213 471 (IQR £53 116 -- £839 713). Public investors funded 73.4% of the research with philanthropic investors funding 18.7%. Industry funding, a major source of investment in clinical trials, could not be accurately sourced and was excluded from this analysis. Operational research accounted for £697 million (26.8%) with the lowest median grants at £88 232 (£18 513 -- £250 423). Philanthropic investors funded 52.7% of the research with public investors funding 42.0%. Trends in investment over time by R&D pipeline is highlighted in [figures S1](#pone.0105722.s001){ref-type="supplementary-material"} and [S2](#pone.0105722.s002){ref-type="supplementary-material"}.

Product development research accounted for the least investment with £133 million (5.1%) with a median grant of £147 621 (IQR £38 625 -- £409 663). Public investors funded 52.0% of the research with philanthropic investors funding 38.0%.

[Table 2](#pone-0105722-t002){ref-type="table"} shows the ranking of funding organisation according to research type. The type of science funded by different organisations clearly varies according to the priorities of each funding organisation. The Wellcome Trust, MRC, European Commission, and BBSRC concentrated their investment on preclinical research (70.6%, 78.4%, 73.6% and 100%, respectively). The Bill and Melinda Gates Foundation, Department of Health and other UK government sources concentrated their research investment on operational research (77.2%, 69.2% and 44.9%, respectively).

10.1371/journal.pone.0105722.t002

###### Ranking of investment in immunology and vaccine research by a) disease system, b) cross-cutting theme, and c) specific infectious disease.

![](pone.0105722.t002){#pone-0105722-t002-2}

  Disease system                      Top funder 1                  Top funder 2                    Top funder 3                     Top funder 4                               Top funder 5
  --------------------------------- ---------------- ------------------------------------------ --------------------- ------------------------------------------ ------------------------------------------
  Gastrointestinal infections            BBSRC                     Wellcome Trust                        MRC                     European Commission                       UK Government, non-DH
                                         33.1%                         31.3%                            13.4%                            8.8%                                       4.7%
  Haematological infections          Wellcome Trust       Bill & Melinda Gates Foundation                MRC                     European Commission                           Other funding
                                         34.2%                         29.9%                            18.4%                            6.7%                                      10.9%
  Hepatic infections                      MRC                      Wellcome Trust                        DH                      European Commission                               BBSRC
                                         33.4%                         19.0%                            12.5%                           11.7%                                       4.6%
  Neglected tropical diseases        Wellcome Trust       Bill & Melinda Gates Foundation                MRC                     European Commission                               BBSRC
                                         45.2%                         29.3%                            14.8%                            9.1%                                       3.8%
  Neurological infections                  DH                      Wellcome Trust                        MRC                Meningitis Research Foundation            Bill & Melinda Gates Foundation
                                         25.3%                         24.9%                            14.9%                           12.1%                                       3.6%
  Ocular infections                  Wellcome Trust                     MRC                            Charity                  UK Government, non-DH                                DH
                                         63.3%                         11.9%                            7.4%                             6.7%                                       6.4%
  Respiratory infections             Wellcome Trust                     MRC                      European Commission                    BBSRC                     Department for International Development
                                         32.3%                         29.6%                            8.0%                             6.2%                                       3.3%
  Sexually-transmitted infections         MRC                            DH                      Cancer Research UK    Department for International Development                Wellcome Trust
                                         29.5%                         19.8%                            19.1%                            9.1%                                       6.5%
  HIV                                     MRC         Department for International Development     Wellcome Trust                European Commission                  Bill & Melinda Gates Foundation
                                         33.8%                         16.6%                            15.8%                           13.5%                                       7.5%
  Overall                            Wellcome Trust                     MRC                      European Commission       Bill & Melinda Gates Foundation                         BBSRC
                                         26.47%                        25.88%                           9.81%                           8.50%                                      7.16%

  Disease system       Top funder 1                Top funder 2                 Top funder 3                 Top funder 4                           Top funder 5
  ---------------- --------------------- --------------------------------- ----------------------- --------------------------------- ------------------------------------------
  Diagnostics               DH                  Cancer Research UK           European Commission         UK Government, non-DH                     Wellcome Trust
                           23.4%                       17.0%                        11.5%                        11.2%                                 10.7%
  Therapeutics      European Commission   Bill & Melinda Gates Foundation      Wellcome Trust                     MRC                 Department for International Development
                           22.6%                       18.5%                        16.5%                        16.0%                                 14.1%
  Vaccines                  MRC                   Wellcome Trust             European Commission    Bill & Melinda Gates Foundation                    BBSRC
                           25.6%                       21.4%                        18.3%                        12.2%                                  6.8%
  Bacteriology        Wellcome Trust                    MRC                         BBSRC                 European Commission                            DH
                           29.9%                       21.8%                        17.7%                        8.2%                                   6.3%
  Mycology                 BBSRC                  Wellcome Trust                     MRC                  European Commission              National Institute for Health
                           30.5%                       24.7%                        16.6%                        13.2%                                  6.2%
  Parasitology        Wellcome Trust      Bill & Melinda Gates Foundation            MRC                  European Commission                          BBSRC
                           41.2%                       25.3%                        15.2%                        12.4%                                  2.8%
  Prion                     DH                  European Commission         UK Government, non-DH                 MRC                              Other funding
                           65.3%                       11.3%                        9.7%                         6.2%                                   7.6%
  Virology                  MRC                   Wellcome Trust             Cancer Research UK           European Commission         Department for International Development
                           35.1%                       18.1%                        10.5%                        8.7%                                   6.9%
  Overall             Wellcome Trust                    MRC                  European Commission    Bill & Melinda Gates Foundation                    BBSRC
                          26.47%                      25.88%                        9.81%                        8.50%                                 7.16%

  Specific infection                      Top funder 1                              Top funder 2                               Top funder 3                             Top funder 4                            Top funder 5
  ------------------------- ---------------------------------------- ------------------------------------------ ------------------------------------------ -------------------------------------- ----------------------------------------
  African trypanosomiasis                Wellcome Trust                                 MRC                          Bill & Melinda Gates Foundation                European Commission                             WHO
                                             75.4%                                     15.3%                                       8.8%                                     0.3%                                    0.1%
  Aspergillus                National Institute for Health Research                Wellcome Trust                         Fungal Research Trust                             MRC                                Other funding
                                             42.8%                                     35.4%                                      13.4%                                     7.4%                                    1.0%
  Campylobacter                              BBSRC                                      MRC                               UK Government, non-DH                        Wellcome Trust                          Other funding
                                             82.2%                                      6.5%                                       6.1%                                     2.7%                                    2.5%
  Candida                    National Institute for Health Research            Fungal Research Trust                      Dunhill Medical Trust                                                   
                                             88.0%                                      9.2%                                       2.7%                                                           
  Chagas disease                         Wellcome Trust                                 MRC                                European Commission                                                    
                                             57.3%                                     23.5%                                      19.2%                                                           
  Chlamydia                           Department of Health                     UK Government, non-DH                               MRC                                 Wellcome Trust                         BUPA Foundation
                                             49.9%                                     15.9%                                      13.5%                                     7.9%                                    4.0%
  Clostridium                                BBSRC                              European Commission                           Wellcome Trust                                MRC                    National Institute for Health Research
                                             24.3%                                     20.3%                                      19.5%                                    17.1%                                   12.6%
  CMV                                         MRC                                  Wellcome Trust                                  NHS                        Bill & Melinda Gates Foundation          National Institute for Health
                                             65.5%                                     24.7%                                       5.6%                                     1.3%                                    0.8%
  Dengue                        Bill & Melinda Gates Foundation                    Wellcome Trust                                  MRC                              European Commission                            BBSRC
                                             76.6%                                     12.5%                                       7.6%                                     2.6%                                    0.8%
  Diphtheria                          European Commission                      UK Government, non-DH                                                                                              
                                             84.5%                                     15.5%                                                                                                      
  E. coli                                    BBSRC                                 Wellcome Trust                                  MRC                      Economic and Social Research Council            European Commission
                                             40.9%                                     39.0%                                       5.8%                                     5.1%                                    3.8%
  EBV                                  Cancer Research UK                               MRC                                   Wellcome Trust                               BBSRC                               Other funding
                                             55.9%                                     25.7%                                      14.7%                                     0.9%                                    2.7%
  Gonorrhoea                             Wellcome Trust                                BBSRC                              UK Government, non-DH                             NHS                                Other funding
                                             48.9%                                     25.6%                                      15.5%                                     4.4%                                    5.6%
  Helicobacter                                MRC                                Cancer Research UK                           Wellcome Trust                                NHS                                Other funding
                                             33.6%                                     28.8%                                      12.2%                                     5.7%                                   19.8%
  Helminths                              Wellcome Trust                   Bill & Melinda Gates Foundation                          MRC                                     BBSRC                            European Commission
                                             53.7%                                     20.0%                                      14.0%                                     7.3%                                    4.5%
  Hepatitis B                                 MRC                                  Wellcome Trust                          European Commission                     National Blood Service                   Department of Health
                                             43.0%                                     23.3%                                       7.2%                                     4.4%                                    3.6%
  Hepatitis C                                 MRC                                  Wellcome Trust                                   DH                              European Commission                    UK Government, non-DH
                                             35.1%                                     17.1%                                      14.3%                                    12.8%                                    4.5%
  HIV                                         MRC                     Department for International Development                Wellcome Trust                        European Commission               Bill & Melinda Gates Foundation
                                             33.8%                                     16.6%                                      15.8%                                    13.5%                                    7.5%
  HPV                                  Cancer Research UK                               MRC                                         DH                              European Commission                        Wellcome Trust
                                             50.8%                                     24.4%                                       9.2%                                     4.9%                                    3.4%
  HSV                                         MRC                                  Wellcome Trust                         UK Government, non-DH                            BBSRC                               Other funding
                                             65.8%                                     23.7%                                       5.4%                                     3.2%                                    2.1%
  Influenza                                   MRC                                      BBSRC                               European Commission                         Wellcome Trust                          Other funding
                                             52.9%                                     16.6%                                      12.9%                                    12.7%                                    4.9%
  Leishmaniasis                          Wellcome Trust                         European Commission                                MRC                                     BBSRC                  
                                             42.5%                                     35.3%                                      18.2%                                     4.0%                  
  Leprosy                                Wellcome Trust                                                                                                                                           
                                             100.0%                                                                                                                                               
  Listeriosis                                BBSRC                                 Wellcome Trust                          European Commission                              MRC                   
                                             40.6%                                     26.2%                                      21.7%                                    11.6%                  
  Lymphatic filariasis          Bill & Melinda Gates Foundation                         MRC                                   Wellcome Trust                                                      
                                             95.5%                                      3.9%                                       0.6%                                                           
  Malaria                                Wellcome Trust                   Bill & Melinda Gates Foundation                          MRC                              European Commission                    UK Government, non-DH
                                             34.5%                                     26.1%                                      19.1%                                    13.0%                                    3.9%
  Measles                                     MRC                               European Commission                       UK Government, non-DH                              DH                                Wellcome Trust
                                             49.2%                                     35.5%                                       7.3%                                     5.3%                                    2.7%
  Meningitis                             Wellcome Trust                    Meningitis Research Foundation                          MRC                                       DH                                Meningitis UK
                                             27.4%                                     22.3%                                      21.2%                                     7.3%                                    4.4%
  Norovirus                              Wellcome Trust                         European Commission                                MRC                                       DH                   
                                             47.7%                                     40.6%                                       9.9%                                     1.8%                  
  Onchocerciasis                      European Commission                          Wellcome Trust                                                                                                 
                                             75.5%                                     24.5%                                                                                                      
  Pertussis                              Wellcome Trust                        UK Government, non-DH                               MRC                                 Other funding              
                                             46.8%                                     31.0%                                      19.5%                                     2.8%                  
  Polio                                       MRC                              UK Government, non-DH                                                                                              
                                             98.5%                                      1.5%                                                                                                      
  Pseudomonas                                 MRC                                      BBSRC                                  Wellcome Trust                                 DH                            UK Government, non-DH
                                             33.2%                                     27.6%                                      10.8%                                     7.4%                                    6.9%
  Rotavirus                              Wellcome Trust                         European Commission                               BBSRC                                     MRC                                Other funding
                                             57.9%                                     20.7%                                      11.2%                                     6.1%                                    4.1%
  RSV                                    Wellcome Trust                                 MRC                                       BBSRC                            UK Government, non-DH                       Other funding
                                             44.8%                                     38.5%                                       5.3%                                     5.2%                                    6.3%
  Salmonella                                 BBSRC                                 Wellcome Trust                                  MRC                              European Commission                        Other funding
                                             55.0%                                     18.4%                                      17.8%                                     8.1%                                    0.7%
  Schistosomiasis               Bill & Melinda Gates Foundation                    Wellcome Trust                          European Commission                             BBSRC                               Other funding
                                             66.2%                                     22.9%                                       8.8%                                     1.3%                                    0.8%
  Shigella                               Wellcome Trust                         European Commission                                MRC                         National Institute for Health      
                                             41.7%                                     25.3%                                      20.0%                                    13.1%                  
  Syphilis                               Wellcome Trust                                 MRC                                         DH                             Terence Higgins Trust          
                                             53.5%                                     21.7%                                      19.5%                                     5.3%                  
  Tetanus                             European Commission                          Wellcome Trust                                                                                                 
                                             83.6%                                     16.5%                                                                                                      
  Trachoma                                    MRC                                                                                                                                                 
                                             100.0%                                                                                                                                               
  Tuberculosis                           Wellcome Trust                                 MRC                      Department for International Development           European Commission               Bill & Melinda Gates Foundation
                                             40.3%                                     23.2%                                       8.9%                                     7.8%                                    6.3%
  VZV                                         MRC                                        DH                                   Wellcome Trust                           Other funding              
                                             45.9%                                     22.5%                                      15.5%                                    16.1%                  
  Overall                                Wellcome Trust                                 MRC                                European Commission                Bill & Melinda Gates Foundation                      BBSRC
                                             26.47%                                    25.88%                                     9.81%                                    8.50%                                   7.16%

BBSRC = Biotechnology and Biological Sciences Research Council. DH = Department of Health. MRC = Medical Research Council. CMV = Cytomegalovirus. EBV = Epstein-Barr virus. HIV = Human immunodeficiency virus. HPV = Human Papillomavirus. HSV = Herpes Simplex virus. RSV = Respiratory Syncytial virus. VZV = Varicella Zoster virus.

Infectious disease system {#s4b}
-------------------------

[Table S1](#pone.0105722.s003){ref-type="supplementary-material"} shows investment by infectious disease system, and specific infection.

The total funding for HIV-related research projects was the greatest with £478 million (18.4%) followed by respiratory infections with £419 million (16.1%), haematological infections with £413 million (15.9%). Gastrointestinal infections received £249 million (9.6%) and NTDs received £230 million (8.8%). Public investors accounted for the majority of research funding for HIV, gastrointestinal, hepatic, respiratory, and sexually transmitted infections. In contrast, philanthropic investors accounted for the majority of research funding for NTDs, haematological infections (primarily malaria) and ophthalmic infections. Largest mean grants were awarded to HIV at £625 073 (SD £2 276 762), with grants by public investors 2.46 fold greater than philanthropic investors. Largest median grants were awarded to NTDs at £248 750 (IQR £91 196--£451 453), with grants by public investors 1.75 fold greater than philanthropic investors.

Specific infection {#s4c}
------------------

Several infections are highly supported by public funding sources compared with philanthropic support. Notable examples include influenza with a 6.38 fold difference (£67.8 million versus £10.6 million), chlamydia with a 9.02 fold difference (£17.7 million versus £2.0 million), campylobacter with a 32.87 fold difference (£22.8 million versus £0.7 million), and salmonella with a 4.39 fold difference (£45.0 million versus £10.2 million). Conversely, philanthropic funding sources greatly outweigh public funding for African Trypanosomiasis (£36.0 million versus £6.7 million), lymphatic filariasis (£45.2 million versus £1.8 million), schistosomiasis (£36.3 million versus £4.4 million), meningitis (£35.3 million versus £16.3 million) and EBV (£32.3 million versus £12.1 million).

Cross-cutting theme {#s4d}
-------------------

Novel technologies to fight infection played an important role in infectious disease research funding. Diagnostics research accounted for £100 million of investment (3.9%), primarily by the Department of Health (23.4%), Cancer Research UK (17.0%) and the European Commission (11.5%). Therapeutics research accounted for £408 million (15.7%), primarily by the European Commission (22.6%), Bill and Melinda Gates Foundation (18.4%) and the Wellcome Trust (16.5%). Vaccine research accounted for £235 million (9.0%), with major funders being the MRC (25.6%), Wellcome Trust (21.4%) and the European Commission (18.3%). Trends in investment over time by technologies to tackle infectious diseases are highlighted in [figures S1](#pone.0105722.s001){ref-type="supplementary-material"} and [S2](#pone.0105722.s002){ref-type="supplementary-material"}. According to type of microbiological organism, viruses were the major area of funding with £1.0 billion (39.5%) followed by parasites with £667 million (25.7%), and bacteria with £588 million (22.6%). Fungal research attracted £48 million (1.9%) and prion research attracted £34 million (1.3%), primarily from the Department of Health. All microbiological categories were funded primarily by public investors, with exception of parasitology where 67.1% of funding came from philanthropic investors.

Discussion {#s5}
==========

We present the first study to systematically analyse the investment by funding organisations for infectious disease research. Funding trends over time highlight the disparities in funding amounts and stage of funding between funding organisations and the infectious diseases they fund. Studies with a clear global health focus, i.e. those performed outside of the UK, in partnership with an international collaborator, or studying a disease primarily affecting a low-income setting, represented 35.7% of total investment (£928 million).

Funding trends over time show that charitable funding declines dramatically from 2007, suggesting that the financial crisis adversely impact on health research funding, in particular from smaller charities that were affected by the economic crisis. The volatility of charitable funding is evident, both as a proportion of total investment as well as the sum of total investment. In contrast, funding for infectious disease research was stable, as a proportion of funding and as total investment, for the large funding organisations such as the Wellcome Trust and MRC. The funding landscape also appears to be shifting. These data highlight the dependence on these two leading funders for health research. In addition, the Bill and Melinda Gates Foundation contribute substantially to infectious disease research funding, interjecting a small number of grants of great monetary value. The European Commission emerges as a major funder, particularly from the year 2000.

Contrasting public and philanthropic funding, total investment is consistently greater from public sources, both in terms of total investment and median investment. Analysing these data over time, the funding from public and philanthropic sources does not appear to be equalising. Fitted values ([figure 5](#pone-0105722-g005){ref-type="fig"}) for public and philanthropic funding do show a trend towards increased financing for research overall. However, a drop in philanthropic funding, attributed to the smaller charitable organisations, is clearly apparent from 2007. It will be important to follow up research investments over the coming years to see whether these trends have reverted.

Of note, there is a lack of industry funding from the data. This is primarily due to the methodological decision to exclude industry funding from the analysis, as the open access data available on R&D investments of pharmaceutical firms clearly underestimated the contribution of industry to infectious disease research. Industry partners are likely to contribute more towards clinical trials such as phase 1, phase 2, and phase 3 studies. In order to make evidence-informed decisions, we require complete and accurate data. The pharmaceutical industry should work alongside public and philanthropic funders in order to map, monitor, and evaluate research funding. Publishing such data online in an open access database, such as on [www.researchinvestments.org](http://www.researchinvestments.org), will be mutually beneficial to both academic institutions and pharmaceutical and biotech companies. In addition, it is unlikely that divulging past and current research investments would jeopardise research in progress. On the contrary, understanding the emerging horizons in current research would allow complementary studies to be performed, and the development of the research base.

We currently lack informative data on the distribution of studies along the research and development pipeline.[@pone.0105722-Rttingen2], [@pone.0105722-Terry1] Data from this analysis shows the weight of preclinical research on funding. The great majority of funding is allocated to preclinical work, with a new minority allocated to phase 1, 2, 3 trials and product development. Operational research, which includes epidemiological studies, attracted the second greatest level of funding. This is particularly strong in global health studies.[@pone.0105722-Zachariah1]--[@pone.0105722-Cobelens1] This trend does not appear to change drastically over time.

We require innovative health financing, and new funding streams to promote innovative delivery of new tools to fight infectious diseases and address the burden of disease.[@pone.0105722-Stuckler1]--[@pone.0105722-Katz2] Funding allocated for tools to tackle infectious diseases on the other hand is more volatile. There is a clear surge in investment from 2000. This investment wanes slightly over the years until further boosts are made from the year 2005. Most of the investment is allocated to therapeutics or studies involving drugs. Vaccine research receives considerable investment, however this tends to be concentrated according to intermittent funding streams.[@pone.0105722-Wolfson1] Diagnostics research appears to be the least well funded of the tools for infectious disease control.

This study maps the research funding landscape for infectious disease research in the UK. The UK is the second greatest funder for global health, after the US.[@pone.0105722-Dorsey1]--[@pone.0105722-Dorsey2] It is essential that we understand the funding contributions from other countries, both from the major world economies of the G20 as well as the investments made by local governments and NGOs in low-income settings.[@pone.0105722-McCoy1] An example of a national system that promotes transparency is the extensive online database on the "Research Portfolio Online Reporting Tools" (RePORT) website by the NIH Research, Condition, and Disease Categorization system (<http://report.nih.gov/catego> rical_spending.aspx). In addition to a lack of openness with industry funding, there is a lack of openness for large grants awarded to international consortia. In the case of these consortia, although the total grant is often well documented, the international transactions between the lead institution and partner institutions are less well documented.

This work has major implications for academic institutions, governments, funding organisations, and policy makers. Particularly with regards to public funding, there is a duty to invest scarce resources wisely.[@pone.0105722-Head2] However, if governments, policy-makers and executives of the funding organisations are allocating resources without accurate knowledge of the current funding terrain, there is bound to be inefficiency.

We urge funding organisations to share data online so that trends in funding may be appropriately assessed. RESIN: Research Investments in Global Health ([www.researchinvestments.org](http://www.researchinvestments.org)) is an initiative that aims to act as an open access portal to facilitate documentation of investments in health research. Inequities in research funding have major implications for global health. Simple measures such as documentation and dissemination of data may act to redress these inequities.
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